secwatch / observer

AleAnna, Inc. — fact timeline

Source-grounded facts extracted from AleAnna, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.

ANNA AleAnna, Inc. JSON
Earnings Releases

AleAnna, Inc. reported first quarter of 2026 results: revenue $8.9 million, net income $3.4 million.

“and future strategic initiatives. Financial and Operational Update Following production ramp-up and stabilization at the Longanesi field during 2025, the Company recognized $8.9 million of revenue during the first quarter of 2026 from sales of its share of production from the Longanesi field. During the first quarter, AleAnna generated net income of $3.4 million”
Governance Changes

AleAnna, Inc.: Amended Articles to extend deadline for initial business combination to June 17, 2025 and to delete the $5,000,001 NTA requirement limitation (effective 2024-03-15).

“At the Meeting, the Company’s shareholders approved a proposal to amend the Company’s amended and restated memorandum and articles of association (the “ Articles ”) to provide the Company with the right to extend the date by which the Company must consummate its initial business combination (the “ Extension ”), from March 15, 2024 to June 17, 2025 (the “ Extension Amendment Proposal ”). The Company’s shareholders also approved a proposal (the “ NTA Requirement Amendment Proposal ”) to amend the Articles of Association to delete: (i) the limitations that the Company shall not consummate a business combination (as defined in the Articles of Association) if it would cause the Company’s net tangible assets (“ NTAs” ) to be less than $5,000,001; and (ii) the limitations that the Company shall not redeem or repurchase its ordinary shares in an amount that would cause the Company’s NTAs to be less than $5,000,001 following such redemptions or repurchases, as applicable (the “ NTA Requirement”
Shareholder Votes

AleAnna, Inc. shareholders approved Adjournment Proposal.

“Approval of Proposal 4 - Adjournment Proposal Votes For Votes Against Abstentions 5,795,220 218,219 111,369”
Shareholder Votes

AleAnna, Inc. shareholders approved NTA Requirement Amendment Proposal.

“Approval of Proposal 3 - NTA Requirement Amendment Proposal Votes For Votes Against Abstentions 5,784,155 229,284 111,369”
Shareholder Votes

AleAnna, Inc. shareholders approved Trust Amendment Proposal.

“Approval of Proposal 2 - Trust Amendment Proposal Votes For Votes Against Abstentions 5,893,439 231,364 5”
Shareholder Votes

AleAnna, Inc. shareholders approved Extension Amendment Proposal.

“Approval of Proposal 1 - Extension Amendment Proposal Votes For Votes Against Abstentions 5,893,439 231,364 5”
Material Agreements

AleAnna, Inc. amended Second Trust Amendment with Continental Share Transfer & Trust Company (effective 2024-03-15).

“On March 15, 2024, the shareholders of Swiftmerge Acquisition Corp. (the “ Company ”) at the reconvened extraordinary general meeting of the Company which had been adjourned from March 13, 2024 (the “ Meeting ”) approved an amendment (the “ Second Trust Amendment ”) of that certain investment management trust agreement, dated December 17, 2021, as amended on June 15, 2023 (the “ Trust Agreement ”), by and between the Company and Continental Share Transfer & Trust Company, a New York corporation, as trustee (“ Continental ”), to change the date on which Continental must commence liquidation of the trust account established in connection with the Company’s initial public offering (the “ Trust Account ”) to the earliest of (i) the Company’s completion of an initial business combination and (ii) June 17, 2025 (the “ Extension Date ”).”
Shareholder Votes

AleAnna, Inc. shareholders approved Approval of adjournment of extraordinary general meeting at the 2024-03-13 meeting.

“The following is a tabulation of the votes with respect to the Adjournment Proposal, which was approved by the Company's shareholders: Approval of Adjournment Proposal Votes For Votes Against Abstentions 5,795,220 218,219 111,369”
Material Agreements

AleAnna, Inc. terminated Merger Agreement and Mutual Termination Agreement with HDL Therapeutics, Inc., and IVCP Merger Sub, Inc. valued at Mutual termination of Merger Agreement; no termination fee. (effective 2024-02-14).

“On February 14, 2024, the Company, HDL and Merger Sub entered into a Mutual Termination Agreement (the “ Mutual Termination Agreement ”) pursuant to which they terminated the Merger Agreement by mutual agreement in accordance with Section 10.1(d) thereof, and each party, on behalf of itself and its agents, released, waived and forever discharged the other parties and their agents of and from any and all obligation or liability arising under the Merger Agreement.”

Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.